AeroVironment Stock Soared on a Blowout Quarter. Is the Drone Boom Just Getting Started?

AeroVironment reported fiscal Q4 revenue of $641.6M (up 133% YoY; ~31% organic), driving adjusted EPS to $1.84 (from $1.61) and lifting adjusted EBITDA margin to 22% (+1700 bps). Funded backlog surged to $1.2B (from $726.6M), and bookings hit $2.7B vs. ~$2.0B revenue (book-to-bill 1.4), reinforcing strong forward demand. Management guided fiscal 2027 revenue to $2.125B-$2.225B (~10% growth at the midpoint) and expects counter-UAS to grow rapidly over 3-5 years; shares jumped >20% to about $171.

Analysis

This is better framed as a procurement-cycle read-through than a standalone earnings beat. The market is likely to overpay for the clearest pure play while underpricing the broader beneficiaries: primes with integrated air-defense stacks and sensor/electronic-warfare leverage such as RTX, NOC, and LMT. The second-order risk for AVAV is mix shift; as counter-UAS scales, the business can become more systems- and integration-heavy, which tends to dilute the very high incremental margins investors are now capitalizing.

Near term, momentum can persist until the next awards/guidance window, but after a sharp rerate the burden of proof moves to execution. The first falsifier for a bullish AVAV thesis is any sign that growth is mostly backlog conversion rather than new demand; if organic growth settles into low-double digits and adjusted EBITDA margin stalls in the low-20s, the multiple is vulnerable. Over 1-3 months, watch DoD and foreign procurement timing; over 6-18 months, the key question is whether counter-UAS becomes a repeatable platform franchise or a collection of one-off products.

Contrarianly, consensus may be too focused on TAM and not enough on competition. Counter-drone is a crowded spend area where incumbents can win through installed base, certification, and bundled procurement, which could pressure AVAV’s share even if the category expands. That argues for owning the broader defense cycle rather than chasing the highest-multiple beneficiary.

Key Decisions for Investors

• Do not chase AVAV after the rerate; prefer to wait for a pullback toward the low-$150s before considering entry. If bought, treat it as a tactical trade, not a core hold, and use a $190-$200 area to trim if execution simply matches current guidance.
• Express the theme through quality defense names: long RTX or LMT vs short AVAV for 1-3 months. This captures counter-UAS and air-defense budget spillover with less valuation risk; thesis breaks if AVAV raises FY27 growth above current expectations or organic growth reaccelerates above ~25%.
• If you want broader beta with lower single-name risk, buy ITA or XAR instead of AVAV. That gives exposure to a defense upcycle without paying 50+ turns of forward earnings for the most crowded name in the basket.
• Watch for a post-earnings or post-award short setup in AVAV only if backlog converts without a new order surprise. A failure to convert the funded backlog into accelerating organic bookings would make the current multiple hard to defend over the next 1-2 quarters.